Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Fig. 3

(a) Rates of ≥50% migraine response by 12-week dosing interval and (b) cumulative 4-week intervals with ≥50% migraine response (efficacy population). *P < 0.001 vs placebo. †Nominal P < 0.001 vs placebo (analyses of migraine responder rates over weeks 13–24 were not formally tested per the predefined statistical hierarchy)

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us